Who
Erin Lavelle
Director
Company insider
Files Form 4 as: Director, Jade Biosciences; Director, Avalyn Pharma; Director, Neurogene; COO & CFO, Climb Bio; Chief Operating Officer, Alder Biopharmaceuticals.
In numbers
- Trades disclosed
- 17
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $20K
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 16 Apr 2018
- Last trade
- 9 Jun 2026
- Last filed
- 11 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 11 Jun 2026 | JBIO Jade Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,843 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | JBIO Jade Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,843 at $0.00 | filing |
| 30 Apr 2026filed 1 May 2026 | AVLN Avalyn Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,978 at $0.00 | filing |
| 30 Apr 2026filed 1 May 2026 | AVLN Avalyn Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,978 at $0.00 | filing |
| 29 Apr 2025filed 1 May 2025 | JBIO Jade Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,017 at $0.00 | filing |
| 8 Jun 2023filed 9 Jun 2023 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 31 Oct 2022filed 2 Nov 2022 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —170,000 at $0.00 | filing |
| 12 May 2022filed 16 May 2022 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 27 Jan 2022filed 31 Jan 2022 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —170,000 at $0.00 | filing |
| 22 Oct 2019filed 24 Oct 2019 | Alder Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —300,000 at $0.00 | filing |
| 22 Oct 2019filed 24 Oct 2019 | Alder Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —150,000 at $0.00 | filing |
| 22 Oct 2019filed 24 Oct 2019 | Alder Biopharmaceuticals | SEC FORM 4 Code A | —11,684 at $0.00 | filing |
| 22 Oct 2019filed 24 Oct 2019 | Alder Biopharmaceuticals | SEC FORM 4 Code U | $290K16,092 at $18.00 | filing |
| 25 Apr 2019filed 25 Apr 2019 | Alder Biopharmaceuticals | SEC FORM 4 Sold | $20K1,434 at $13.67 | filing |
| 23 Apr 2019filed 25 Apr 2019 | Alder Biopharmaceuticals | SEC FORM 4 Code A | —5,842 at $0.00 | filing |
| 6 Feb 2019filed 8 Feb 2019 | Alder Biopharmaceuticalsoption or derivative | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 16 Apr 2018filed 18 Apr 2018 | Alder Biopharmaceuticalsoption or derivative | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.